Enhertu) has compiled an impressive record as treatment for HER2-positive breast cancer. The agent outperformed T-DM1 in a randomized trial in HER2-positive metastatic breast cancer and ...

AstraZeneca and Daiichi Sankyo's Enhertu has become the first HER2-directed drug to mount a patient survival benefit in a ...

T-DM1 contains a boxed warning from the FDA. This is the strongest possible warning the FDA requires and indicates that a drug has a significant risk for serious or life threatening adverse effects.

Enhertu is approved for HR-positive ... That study was overall positive, including a subset of patients with ultralow, although that subset was small and didn't have the statistical power on its own ...

AstraZeneca and Daiichi Sankyo’s Enhertu should not be made available via the NHS for HER2-low metastatic or unresectable breast cancer after chemotherapy, according to provisional guidance from ...

Just days after the FDA approved AstraZeneca and Daiichi Sankyo's Enhertu for a potentially lucrative new use, the regulatory has now cleared a diagnostic test that could help unlock the drug's ...

Feb 28 (Reuters) - The European Union's health regulator on Friday backed AstraZeneca (AZN.L), opens new tab and Daiichi Sankyo's (4568.T), opens new tab drug Enhertu as a breast cancer treatment ...

Daiichi Sankyo and AstraZeneca’s Enhertu (trastuzumab deruxtecan) has shown clinically meaningful 'improvement' in the DESTINY-Gastric04 Phase III trial, regarding the primary endpoint of ...